Floatz logo
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Ospedale di Camposampiero
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Recruiting
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
Recruiting
Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.
Completed
Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery
Completed
Different Volumes of Erector Spinae Plane Block for Breast Surgery
Completed
Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy
Unknown
RCT Comparing ESPB Solutions in Breast Surgery
Completed
Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries
Completed
Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy
Completed
Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery
Completed
Show 17 more trials
Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies
Withdrawn
Speeding Recovery From Pain and Opioid Use
Withdrawn
Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction
Withdrawn
Post Mastectomy Pain Syndrome After Preoperative Stellate Ganglion Block for Breast Cancer Surgeries
Unknown
Erector Spinae Plane Block Versus Serratus Plane Block for Breast Surgery
Completed
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
Recruiting
PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Completed
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Completed
Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block
Completed
CWI and Discharge After Breast Cancer Surgery
Completed
Nerveblocks for Persistent Pain After Breast Cancer Surgery
Unknown
Using Bupivacaine Locally in the Mastectomy Drains to Control Postoperative Pain
Completed
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Completed
Liposomal Bupivacaine in Implant Based Breast Reconstruction
Terminated
Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Completed
Use of Continuous Wound Infusion of Bupivacaine for Analgesia Following Axillary Clearance Surgery
Unknown
Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?
Completed

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Breast Cancer

AssetSponsorPhaseRating
Marcaine (this asset)Ospedale di CamposampieroApprovedBB · 68
DarolutamideVandana AbramsonP2BBB
PertuzumabSWOG Cancer Research NetworkP4BB
PalbociclibHoffmann-La RocheP4BB
Trastuzumab DuocarmazineByondis B.V.P3BB
GoserelinTerSera Therapeutics LLCP4BB
RibociclibNational Cancer Institute (NCI)P4BB
OxaliplatinBeijing Biostar Pharmaceuticals Co., Ltd.P4BB
Eribulin MonomethanesulfonateHenan Cancer HospitalP4BB

+42 more in the Breast Cancer cohort

Other indications for Marcaine

IndicationSponsorPhaseRating
Migraine DisorderP4BBB · 74
NeuralgiaP4BBB · 74
Headache DisorderP4BBB · 73

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Marcaine in Breast Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/1-butyl-26-pipecoloxylidide-monohydrochloride-breast-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →